FDAnews

YM BIOSCIENCES BEGINS NON-SMALL-CELL LUNG CANCER TRIAL WITH NIMOTUZUMAB

YM BioSciences has announced that the first patient has been enrolled in its multicenter Phase I/II non-small-cell lung cancer (NSCLC) trial utilizing the company's anti-EGFr monoclonal antibody, nimotuzumab (TheraCIM). The randomized Phase II part of the trial will compare the effects of the combination of nimotuzumab with radiation against radiation alone in patients with Stage IIB and III disease who are found to be insufficiently fit to tolerate the standard-of-care or who are not amenable to treatment with curative intent.

The Phase I portion of the trial will be an open-label dose-escalation study in which increasing doses of nimotuzumab will be studied in combination with palliative radiation in patients with Stage IIB and III disease who are unable to receive standard chemoradiation treatment with curative intent.